Progeria

Progeria, or Hutchinson–Gilford progeria syndrome, is a fatal childhood disease caused by a single recurrent point mutation in LMNA, the gene encoding the nuclear structural proteins lamin A and lamin C. The mutation activates a hidden splice site and produces progerin, a shortened lamin A that stays permanently anchored in the nuclear membrane and distorts the nucleus. Affected children grow poorly, lose hair and subcutaneous fat, develop severe atherosclerosis, and die at an average age of about 14.5 years, more than 80% of them from heart failure or myocardial infarction.¹ Aging research invokes the disease constantly as a natural experiment in acceleration, and how much it deserves that role is contested.

§The mutation

Roughly 90% of cases carry the same substitution, c.1824C>T, arising fresh in the affected child rather than inherited. The change is silent at the level of the genetic code: it converts one glycine codon into another and alters no amino acid. What it does instead is strengthen a cryptic splice donor site inside exon 11, so that a fraction of LMNA transcripts are spliced short.²

The resulting protein lacks fifty amino acids near its C-terminus. Normal prelamin A is farnesylated, inserted into the inner nuclear membrane, and then cleaved by the protease ZMPSTE24, which removes the farnesylated tail and releases mature lamin A. The fifty-residue deletion takes the cleavage site with it. Progerin therefore keeps its lipid anchor and never leaves the membrane, and it accumulates.

Cells carrying progerin show lobulated nuclei, loss of peripheral heterochromatin, altered histone modification, a persistent DNA damage response, and early entry into Cellular senescence in culture. Because the defect is structural rather than enzymatic, no single downstream pathway explains the whole phenotype, which is part of why the disease has been easier to describe than to treat.

§What the disease does, and what it spares

Growth failure appears in the first year, alongside hair loss, loss of subcutaneous fat, tight and stippled skin, delayed tooth eruption, and a characteristic facial appearance. Joint contractures, bone changes, and hearing loss follow. The vascular lesion is the one that kills: smooth muscle cells are lost from the arterial wall and replaced by fibrous tissue, producing stroke and myocardial infarction in the first or second decade.

What the disease leaves alone is as informative as what it damages. Motor and cognitive development are normal throughout. Liver, kidney, gastrointestinal, and immune function are normal. The tumour rate is not raised above that of the general population,¹ which sets it apart both from most conditions resembling accelerated aging and from Cancer risk in ordinary old age.

Birth incidence is around one in four million. The Progeria Research Foundation, which maintains the international registry, had identified 163 people living with the syndrome as of mid-2026, and 223 counting the related progeroid laminopathies, spread across 55 countries.³

§Finding the gene

1. 1886–1897
   First descriptions
   Jonathan Hutchinson reports a boy with absent hair and aged skin; Hastings Gilford describes further cases and coins the term progeria, from the Greek for prematurely old.
2. 1999
   Progeria Research Foundation founded
   Started by the parents of an affected child, it builds the patient registry, diagnostic programme, and cell bank that later research depends on.
3. 2003
   LMNA identified
   Two groups independently trace the syndrome to lamin A; the recurrent silent substitution and the resulting truncated protein are described.
4. 2007
   First lonafarnib trial
   A single-arm trial of the farnesyltransferase inhibitor opens at Boston Children's Hospital.
5. 2018
   Survival signal reported
   Treated patients are compared with a matched contemporaneous untreated cohort and show lower mortality.
6. 2020
   Lonafarnib approved
   The FDA approves Zokinvy in November, the first approved treatment for the disease.
7. 2021
   Base editing rescues progeria mice
   A single injection of an AAV-delivered adenine base editor roughly doubles the median lifespan of mice carrying the human mutation.
8. 2026
   Manufacturing agreement
   The foundation contracts a manufacturer to produce clinical-grade material for its gene-editing candidate ahead of regulatory review.

The gene resisted mapping for a century because the disease is sporadic: there are no affected families to link, and until a registry existed there were barely enough patients to study. Maria Eriksson, Francis Collins, and colleagues at the National Human Genome Research Institute solved it in 2003 using a small patient series assembled through the foundation, and De Sandre-Giovannoli's group in Marseille reported LMNA lesions independently the same year.²

§Farnesyltransferase inhibition

Progerin's damage depends on the farnesyl group it never sheds, which made blocking protein farnesylation an obvious target — and farnesyltransferase inhibitors already existed, developed for cancer. Lonafarnib entered single-arm trials in 2007. A 2018 analysis compared treated patients with untreated patients matched by age, sex, and continent, and reported lower mortality in the treated group.⁴

The FDA approved lonafarnib as Zokinvy in November 2020, to reduce mortality risk in progeria and to treat processing-deficient progeroid laminopathies. The agency's own summary of the decision describes 62 treated patients drawn from two open-label trials and compared with matched untreated patients from a natural history study: mortality fell by 60%, and mean survival rose by 2.5 years across a maximum follow-up of 11 years.⁵ The drug does not correct the mutation, and treated children still develop cardiovascular disease.

The evidence base is an external control, not a trial arm

No randomised controlled trial has ever been run in progeria, and with roughly 160 identified patients worldwide it is unlikely one ever will be. Every survival estimate for lonafarnib compares treated children with untreated children identified separately, which cannot exclude differences in ascertainment, diagnosis date, or standard of care. The effect is the best-supported claim in the field and it is still not a randomised one.

Later trials combined lonafarnib with other agents, including everolimus, an mTOR inhibitor in the same class as Rapamycin, and a trial of a progerin-binding compound alongside lonafarnib was enrolling in 2026.³

§Correcting the letter

A disease caused by one base substitution is the cleanest possible target for Base editing, a modification of CRISPR–Cas9 that converts one base pair to another without cutting both DNA strands. In 2021, Luke Koblan and colleagues in David Liu's laboratory, working with the NHGRI group, delivered an adenine base editor by AAV9 to mice engineered to carry the human progeria mutation. A single injection at postnatal day 14 raised median lifespan from 215 to 510 days and largely preserved the aortic smooth muscle that is destroyed in untreated animals. In cultured fibroblasts from children with the syndrome, lentiviral delivery of the same editor corrected 87–91% of the pathogenic allele and reduced progerin.⁶

Every lifespan number in that work is a mouse number. No person has received the editor. The foundation's candidate, an AAV-delivered base editor, was contracted to a manufacturer for clinical-grade production in March 2026, and the foundation describes manufacturing, engagement with the FDA, and protocol development as the steps still standing between the programme and a first trial.³ Unlike Casgevy, where cells are edited outside the body and returned, this means editing the vasculature in place, the delivery problem that has limited Somatic gene therapy generally. Off-target editing in a child expected to live for decades is the safety question a regulator will press hardest on, and it is not answered by mouse survival.

§Accelerated aging, or a phenocopy

Whether progeria is aging at speed

One camp treats the syndrome as normal aging compressed: it shares genome instability, telomere attrition, premature senescence and stem-cell depletion with ordinary aging, and progerin itself is made at low levels in unaffected people through sporadic use of the same splice site. The other treats it as a segmental disease that copies some of aging's output through a mechanism aging does not use — no raised cancer risk, no cognitive decline, and a distinctive vascular lesion rather than the usual atherosclerotic one. Nothing in the genetics settles which reading is right, and the therapeutic stakes differ: on the first reading a progeria cure is a lead on aging, on the second it is a cure for progeria.

The strongest evidence for the continuity view is that progerin is not confined to patients. Paola Scaffidi and Tom Misteli showed in 2006 that the cryptic splice site is used sporadically in healthy cells, that nuclei from old donors acquire defects resembling those of progeria cells, and that blocking the splice site reverses those defects; a subsequent screen of 150 skin biopsies from unaffected people aged newborn to 97 found progerin protein accumulating with age even though its transcript stayed rare.⁷

The evidence against runs through what the syndrome omits. Standard DNA methylation clocks, the most widely used measures of Biological age, detect no age acceleration in progeria cells at all; a clock trained specifically on skin and blood does find some, but of a magnitude the earlier estimators could not resolve.⁸ Christopher Burtner and Brian Kennedy, reviewing the progeroid syndromes, treat the overlap in molecular changes as real and the inference from it as unsettled: shared mechanisms establish that the syndromes touch aging biology, not that they run it faster.⁹

Werner syndrome sharpens the contrast. Caused by loss of the WRN RecQ helicase, it is recessive, spares childhood entirely, and produces cataracts, diabetes, osteoporosis, and sarcomas, with death usually in middle age from cancer or myocardial infarction.⁹ Two diseases both called progeroid pick out different fragments of old age, which is what a phenocopy account predicts and an acceleration account has to explain.

§Outlook

The mouse result is the reason the disease matters beyond its 163 patients. It shows that in a mammal, a single-base correction delivered after birth can arrest a systemic degenerative phenotype rather than merely slow it, which is a stronger claim than most of what Gene therapy for aging can currently point to. It is also the shape of result the Geroscience hypothesis predicts: one upstream correction, several downstream pathologies delayed. The qualifications are equally specific. The editor went in on postnatal day 14, before the vascular damage was established; children entering a trial would already have arterial disease. And the lesson does not obviously generalise, because normal aging is not one base.

That caution applies in the other direction too. Progeria mice are a convenient model, and results obtained in them travel further than they should — the founding in vivo demonstration of Partial reprogramming extended lifespan in mice carrying a progeria-causing lamin A mutation, while the same protocol in normally aging animals improved injury repair without a reported lifespan gain.¹⁰ Whatever progeria turns out to be, it is not a small copy of aging that can be substituted for the real thing when the real thing is inconvenient to study.

§See also

• Hallmarks of aging
• Base editing
• Cellular senescence
• Epigenetic reprogramming
• Somatic gene therapy
• Biological age
• Geroscience hypothesis
• Maximum human lifespan

§References